Due to a collaborative agreement with IPT closed in 2008, Lewa's US subsidiary has been able break into the North American biopharmaceutical downstream systems markets. The acquisition will advance this development and "complement the existing competence of LEWA-NIKKISO in this field, increasing the corporate value of the group," explains Naota Shikano, CEO of Lewa.